Enteric-Coated Mycophenolate Sodium

Annals of Pharmacotherapy

Volumn 37, Issue 11, 2003, Pages 1685-1693

  Gabardi, Steven ^a,b   Tran, Jennifer L ^b   Clarkson, Michael R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

EC MPS; ERL; ERL080; MPS; Mycophenolate sodium; Mycophenolic acid; Renal transplantation; Solid organ transplantation

Indexed keywords

ACICLOVIR; ANTACID AGENT; ANTIBIOTIC AGENT; COLESTYRAMINE; COTRIMOXAZOLE; CYCLOSPORIN; FERROUS SULFATE; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PREDNISONE; RAPAMYCIN; SULFINPYRAZONE; TACROLIMUS;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPEPSIA; ENTERIC COATED TABLET; ENZYME INHIBITION; FATIGUE; FEVER; FLATULENCE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL INFECTION; GRAFT REJECTION; HEADACHE; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SWITZERLAND; TERATOGENICITY; THROMBOCYTOPENIA; UNITED STATES; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; RANDOMIZED CONTROLLED TRIALS; TABLETS, ENTERIC-COATED;

EID: 0142244563     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D063     Document Type: Review

References (46)

1. Watts RW. Some regulatory and integrative aspects of purine nucleotide biosynthesis and its control: an overview. Adv Enzyme Regul 1983;21: 33-51.
2. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-9.
3. Suzuki S, Kimura T, Ando K, Sawada T, Tamura G. Antitumor activity of mycophenolic acid. J Antibiot 1969;22:297-302.
4. Ohsugi U, Hirose S, Juji G. Immunosuppressive effects of mycophenolic acid. Prolongation of survival time of skin allografts. Transplantation J 1972;7:257-9.
5. Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1979;1:531-7.
6. Lynch WS, Roenigk HH. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8.
7. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL. Mycophenolic acid in the treatment of psoriasis. Arch Dermatol 1977;113:930-2.
8. Spatz S, Rudnicka A, McDonald CJ. Mycophenolic acid in psoriasis. Br J Dermatol 1978;98:429-35.
9. Nelson P, Eugui E, Allison AC. Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Medicinal Chem 1990;33:833-8.
10. Lee W, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990;7:161-6.
11. Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, et al. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178-97.
12. Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993;56:75-82.
13. European Mycophenolate Mofetil Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroid for prevention of acute rejection. Lancet 1995;345:1321-5.
14. Scollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
15. Scollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443 - a Phase I clinical trial and pilot rescue study. Transplantation 1992;53:428-32.
16. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996:61:1029-37.
17. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three year experience in heart transplantation. J Heart Lung Transplant 1994;13:571-83.
18. Package insert. CellCept (mycophenolate mofetil). Nutley, NJ: Roche Laboratories, March 2003.
19. Pelletier RP. Mycophenolate mofetil dose reduction influences clinical outcome following kidney transplantation (abstract). Presented at: American Transplant Congress, Washington, DC, April 28-May 1, 2002.
20. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and ester prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28.
21. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
22. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenase as targets. Ann NY Acad Sci 1993;696:88-93.
23. Scollinger HW, Eugui EM, Allison AC. RS-61443: mechanism of action, experimental and early clinical trial results. Clin Transplant 1991; 5:523-6.
24. Allison AC, Ahlmquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolate acid and an ester prodrug, RS-61443. Transplant Proc 1991;23(2 suppl 2):10-4.
25. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991;33:175-83.
26. Lauren AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996; 24:59-67.
27. Woo J, Zeevi A, Yao GZ, Strednak J, Todo S, Thomson AW. Effects of FK-506, mycophenolic acid and bredinin on OKT3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. Transplant Proc 1991;23:2939-40.
28. Zeevi A, Woan M, Yao GZ, Venkataramanan R, Todo S, Starzl TE, et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK-506, cyclosporine, and rapamycin. Transplant Proc 1991;23:2928-30.
29. Zeevi A, Yao GZ, Venkataramanan R, Duquesnoy RJ, Todo S, Fung JJ, et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc 1993;25:781.
30. American Medical Association. Statement of nonproprietary name adopted by the USAN council. www.ama-assn.org/ama/pub/printcat/ 7478.html (accessed 2003 Sept 13).
31. Budde K, Glander P, Hahn U, Roblitz H, Mai I, Diekmann F, et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance renal transplant patients (abstract). Presented at: American Transplant Congress, Washington, DC, April 28-May 1, 2002.
32. Package insert. Myfortic (mycophenolate sodium). Berne, Switzerland: Novartis Pharma, May 2002.
33. De Mattos A, Salvadori M, Sollinger H, Kumar MSA, Holzer H, Civati G, et al. Enteric coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients (abstract 3275). Presented at: XIX International Congress of the Transplantation Society, Miami, FL, August 25-30, 2002.
34. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001;33:3241-4.
35. Salvadori M. Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients. Transplant Proc 2001;33:3245-7.
36. Salvadori M, Sollinger H, Kumar M, De Mattos H, Holzer R, Brambilla, et al. Therapeutic equivalence of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) vs. mycophenolate mofetil (MMF) at 12 months in de novo renal transplant patients (abstract 1035). Presented at: American Transplant Congress, Washington, DC, April 28-May 1, 2002.
37. Schmouder RL, Fauchald P, Arns W, Sperschneider H, Choi L, Graf P, et al. Enteric-coated mycophenolate sodium delivers therapeutic mycophenolate acid exposure to more patients than mycophenolate mofetil (abstract 2124). Presented at: XIX International Congress of the Transplantation Society, Miami, FL, August 25-30, 2002.
38. Schmouder RL, Fauchald P, Arns W, Sperschneider H, Choi L, Graf P, et al. Systemic exposure of mycophenolic acid (MPA) is greater with Myfortic than MMF (abstract 380). Presented at: American Transplant Congress, Washington, DC, April 28-May 1, 2002.
39. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolate acid: report of a roundtable discussion. Ther Drug Monit 2001;23:305-15.
40. Neumayer HH, Curtis J, Knoll G, Granger D, Budde K, Panis C, et al. Maintenance renal transplant patients can be safely switched from mycophenolate mofetil to enteric-coated mycophenolate sodium (abstract 2129). Presented at: XIX International Congress of the Transplantation Society, Miami, FL, August 25-30, 2002.
41. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-63.
42. Zhu W, Arns W, Carpenter P, Choi L, Prasad P, Choudhury S, et al. Cyclosporine is associated with decreased absolute bioavailability of mycophenolic acid (abstract). Presented at: American Transplant Congress, Chicago, IL, May 2001.
43. Morii M, Ueno K, Ogawa A, Kato R, Yoshimura H, Wada K, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000;68:613-6.
44. Catalano C, Fabbian F, Bordin V, Di Landro D. Mycophenolate mofetil toxicity in an anorexic kidney transplant patient treated with sulphinpirazone. Nephrol Dial Transplant 1997;12:2467-8.
45. Ettenger R, Choi L, Al-Akash S, Zhu W, Starr J, Schmouder R. Myfortic delivers therapeutic mycophenolic acid exposure in pediatric renal transplant patients (abstract 216). Presented at: American Transplant Congress, Washington, DC, April 28-May 1, 2002.
46. Ettenger R, Choi L, Al-Akash S, Zhu W, Schmouder R, Starr J. Single dose pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients: preliminary results (abstract 2477). Presented at: XIX International Congress of the Transplantation Society, Miami, FL, August 25-30, 2002.